Opioid Analgesics and Routes of Administration

Cancer Pain

Volumn , Issue , 2006, Pages 171-193

  Vascello, Luis ^a   McQuillan, Robert J ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Department of Anesthesiology ^*  (United States)

^c CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76949089497     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0261-5.50021-1     Document Type: Chapter

References (213)

1. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain 1999, American Pain Society, Glenview, IL. Fourth Edition.
2. Foley KM The treatment of cancer pain. N Engl J Med 1985, 313:84-95.
3. Daut RL, Cleeland CS The prevalence and severity of pain in cancer. Cancer 1982, 50:1913-1918.
4. Twycross R Pain Relief in Advanced Cancer 1994, Churchill Livingstone, London.
5. World Health Organization Cancer Pain Relief 1986, World Health Organization, Geneva, Switzerland.
6. World Health Organization Cancer Pain Relief with a Guide to Opioid Availability 1996, World Health Organization, Geneva, Switzerland.
7. Agency for Health Care Policy and Research Management of Cancer Pain. A Clinical Practice Guideline 1994, AHCPR, Rockville, MD, March.
8. Hanks GW, Justins DM Cancer pain: Management. Lancet 1992, 339:1031-1036.
9. Schug SA, Zech D, Don U Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990, 5:27-32.
10. Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991, 6:411-422.
11. McCaffery M Pain control. Barriers to the use of available information. World Health Organization Expert Committee on Cancer Pain Relief and Active Supportive Care. Cancer 1992, 70:1438-1449.
12. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain 1995, 63:65-76.
13. Practice guidelines for cancer pain management A report by the American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Anesthesiology 1996, 84:1243-1257.
14. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA 1995, 274:1874-1880.
15. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain 1994, Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, Rockville, MD, Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592, March.
16. Levy MH Supportive oncology: Forward. Semin Oncol 1994, 21:699-700.
17. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001, 93:247-257.
18. Poole SC, Sahr JS Opiate receptors: A review of analgesic properties and pharmacological side effects. J La State Med Soc 1992, 144:106-108.
19. Goldstein DJ, Meador-Woodruff JH Opiate receptors: Opioid agonist-antagonist effects. Pharmacotherapy 1991, 11:164-167.
20. Deutsch SI, Weizman A, Goldman ME, et al. The sigma receptor: A novel site implicated in psychosis and antipsychotic drug efficacy. Clin Neuropharmacol 1988, 11:105-119.
21. Musacchio SM The psychotomimetic effects of opiates and the sigma receptor. Neuropsychopharmacology 1990, 3:191-200.
22. Davies G, Kingswood C, Street M Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996, 31:410-422.
23. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983, 13:180-185.
24. Christrup LL Morphine metabolites. Acta Anaesthesiol Scand 1997, 41:116-122.
25. Smith MT, Watt JA, Cramond T Morphine-3-glucuronide-a potent antagonist of morphine analgesia. Life Sci 1990, 47:579-585.
26. Bruera E, Macmillan K, Hanson J, et al. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989, 39:13-16.
27. Bruera E, Pereira S, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996, 78:852-857.
28. de Stoutz ND, Bruera E, Suarez AM Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10:378-384.
29. Ripamonti C, Zecca E, Bruera E An update on the clinical use of methadone for cancer pain. Pain 1997, 70:109-115.
30. Sjogren P, Jensen NH, Jensen TS Disappearance of morphine-induced hyper-algesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994, 59:313-316.
31. Thomas Z, Bruera E Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995, 10:315-317.
32. Walsh TD Prevention of opioid side effects. J Pain Symptom Manage 1990, 5:362-367.
33. Bruera E, Miller MS, Macmillan K, et al. Neuropsychological effects of methylphe-nidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992, 48:163-166.
34. Bruera E, Brenneis C, Paterson AN, et al. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989, 4:3-6.
35. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988, 94:1351-1356.
36. Bruera E, Schoeller T, Montejo G Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992, 48:397-399.
37. Lawlor PG The Panorama of opioid-related cognitive dysfunction in patients with cancer: A critical literature appraisal. Cancer: 2002, 94:1836-1853.
38. Hardman JG, Limbird LE, Gilman AG Goodman and Gilman's The Pharmacological Basis of Therapeutics 2001, McGraw-Hill, New York. 10th ed.
39. Foley KM Controversies in cancer pain. Medical perspectives. Cancer 1989, 63:2257-2265.
40. Collin E, Poulain P, Gauvain-Piquard A, et al. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment?. Pain 1993, 55:319-326.
41. Doyle D Morphine: Myths, morality and economics. Postgrad Med J 1991, 67(Suppl 2):S70-S73.
42. Schug SA, Zech D, Grond S, et al. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992, 7:259-266.
43. Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: The EAPC recommendations. Expert Working Group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001, 84:587-593.
44. Klepstad P, Kaasa S, Jystad A, et al. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: A randomized, double-blind trial. Pain 2003, 101:193-198.
45. Sawe J High-dose morphine and metha-done in cancer patients. Clinical pharma-cokinetic considerations of oral treatment. Clin Pharmacokinet 1986, 11:87-106.
46. Sawe S, Dahlstrom B, Rane A Steady-state kinetics and analgesic effect of oral morphine in cancer patients. Eur J Clin Pharmacol 1983, 24:537-542.
47. Savarese JJ, Goldenheim PD, Thomas GB, et al. Steady-state pharmacokinetics of controlled release oral morphine sulfate in healthy subjects. Clin Pharmacokinet 1986, 11:505-510.
48. Poulain P, Hoskin PJ, Hanks GW, et al. Relative bioavailability of controlled release morphine tablets (MST continuous) in cancer patients. Br J Anaesth 1988, 61:569-574.
49. Hanks GW Controlled-release morphine (MST Contin) in advanced cancer. The European experience. Cancer 1989, 63:2378-2382.
50. Warfield CA Guidelines for the use of MS Contin tablets in the management of cancer pain. Postgrad Med J 1991, 67(Suppl 2):S9-S12.
51. Thirlwell MP, Sloan PA, Maroun SA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989, 63:2275-2283.
52. Kaiko RF, Grandy RP, Oshlack B, et al. The United States experience with oral controlled-release morphine (MS Contin tablets). Parts I and II. Review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjects. Cancer 1989, 63:2348-2354.
53. Finn SW, Walsh TD, MacDonald N, et al. Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer. J Clin Oncol 1993, 11:967-972.
54. Bass S, Shepard KV, Lee SW, et al. An evaluation of the effect of food on the oral bioavailability of sustained-release morphine sulfate tablets (ORAMORPH SR) after multiple doses. J Clin Pharmacol 1992, 32:1003-1007.
55. Drake S, Kirkpatrick CT, Aliyar CA, et al. Effect of food on the comparative pharma-cokinetics of modified-release morphine tablet formulations: Oramorph SR and MST Continuous. Br J Clin Pharmacol 1996, 41:417-420.
56. Hunt TL, Kaiko RF Comparison of the pharmacokinetic profiles of two oral controlled-release morphine formulations in healthy young adults. Clin Ther 1991, 13:482-488.
57. Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997, 14:63-73.
58. Gourlay GK, Cherry DA, Onley MM, et al. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997, 69:295-302.
59. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002, 23:278-291.
60. Portenoy RK, Sciberras A, Eliot L, et al. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002, 23:292-300.
61. Portenoy RK, Thaler HT, Inturrisi CE, et al. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992, 51:422-431.
62. Klepstad P, Kaasa S, Borchgrevink PC Start of oral morphine to cancer patients: Effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000, 55:713-779.
63. Paternak GW, Bodnar RJ, Clark JA, et al. Morphine-6-glucuronide, a potent mu agonist. Life Sci 1987, 41:2845-2849.
64. Sarton E, Teppema L, Nieuwenhuijs D, et al. Opioid effect on breathing frequency and thermogenesis in mice lacking exon 2 of the mu-opioid receptor gene. Adv Exp Med Biol 2001, 499:399-404.
65. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992, 34:130-138.
66. Thompson PI, Joel SP, John L, et al. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995, 40:145-152.
67. Romberg R, Olofsen E, Sarton E, et al. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. Anesthesiology 2003, 99:788-799.
68. Gorman AL, Elliott KS, Inturrisi CE The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997, 223:5-8.
69. Mao S, Price DD, Mayer DJ Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain 1995, 62:259-274.
70. Dickenson AN NIMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand 1997, 41:112-115.
71. Leng G, Finnegan MS Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994, 8:153-155.
72. Crews JC, Sweeney NJ, Denson DD Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain. Case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993, 72:2266-2272.
73. Manfredi PL, Borsook D, Chandler SW, et al. Intravenous methadone for cancer pain unrelieved by morphine and hydro-morphone: Clinical observations. Pain 1997, 70:99-101.
74. Fitzgibbon DR, Ready LB Intravenous high-dose methadone administered by patient controlled analgesia and continuous infusion for the treatment of cancer pain refractory to high-dose morphine. Pain 1997, 73:259-261.
75. Plunmier JL, Gourlay GK, Cherry DA, et al. Estimation of methadone clearance: Application in the management of cancer pain. Pain 1988, 33:313-322.
76. Mercadante S, Sapio M, Serretta R, et al. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Ann Oncol 1996, 7:613-617.
77. Sawe I, Hansen I, Ginman C, et al. Patient controlled dose regimen of methadone for chronic cancer pain. BMJ 1981, 282:771-773.
78. Manfredi PL, Gonzalez GR, Cheville AL, et al. Methadone analgesia in cancer patients on chronic methadone maintenance therapy. J Pain Symptom Manage 2001, 21:169-174.
79. Hays H, Hagen N, Thirlwell M, et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994, 74:1808-1816.
80. Poyhia R, Vaiio A, Kalso E A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993, 8:63-67.
81. Ross FB, Smith MT The intrinsic antino-ciceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997, 73:151-157.
82. Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992, 14:479-484.
83. Kalso E, Vaiio A, Mattila MI, et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990, 67:322-328.
84. Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state pharma-cokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992, 52:487-495.
85. Heiskanen T, Kalso E Controlled-release oxycodone and morphine in cancer related pain. Pain 1997, 73:37-45.
86. Poyhia R, Seppala T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992, 33:617-621.
87. Hoskin PS, Hanks GW, Aheme GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989, 27:499-505.
88. Osborne R, Joel S, Trew D, et al. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990, 47:12-19.
89. Beaver WT, Wallenstein SL, Rogers A, et al. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. J Pharmacol Exp Ther 1978, 207:101-108.
90. Mandema SW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996, 42:747-756.
91. Roy SD, Flynn GL Solubility and related physicochemical properties of narcotic analgesics. Pharm Res 1988, 5:580-586.
92. Kaiko R, Lacouture P, Hopf K, et al. Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine. Clin Pharmacol Ther 1996, 59:130. (abst).
93. Reder RF, Oshlack B, Miotto SB, et al. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clin Ther 1996, 18:95-105.
94. Klepper ID, Sherrill DL, Boetger CL, et al. Analgesia and respiratory effects of extradural sufentanil in volunteers, and the influence of adrenaline as an adjuvant. Br J Anesth 1987, 59:1147-1155.
95. Hansdottir V, Hedner T, Woestenborghs R, et al. The CSF and plasma pharmaco-kinetics of sufentanil after intrathecal administration. Anesthesiology 1992, 74:264-270.
96. Yaksh TL Spinal opiates: a review of their effect on spinal function with emphasis on pain processing. Acta Anaesthesiol Scand 1987, 31:25-37.
97. Yaksh TL, Noueihed R The physiology and pharmacology of spinal opioids. Annu Rev Pharmocol Toxicol 1985, 25:433-445.
98. Roy SD, Flynn GL Transdermal delivery of narcotic analgesics: pH, anatomical, and subject influences on cutaneous permeability of fentanyl and sufentanil. Pharm Res 1990, 7:842-847.
99. Dormer B, Zenz M, Tiyba M, et al. Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain 1996, 64:527-534.
100. Dormer B, Zenz M, Strumpf M, et al. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998, 15:168-175.
101. Grond S, Zech D, Lehmann KA, et al. Transdermal fentanyl in the long-term treatment of cancer pain: A prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997, 69:191-198.
102. Korte W, de Stoutz N, Morant R Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996, 11:139-146.
103. Payne R Transdermal fentanyl: Suggested recommendations for clinical use. J Pain Symptom Manage 1992, 7:S40-S44.
104. Payne R, Chandler S, Einhaus M Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 1995, 6(Suppl 3):50-53.
105. Payne R, Mathias SD, Pasta DI, et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998, 16:1588-1593.
106. Plezia PM, Kramer TH, Linford J, et al. Transdermal fentanyl: Pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy 1989, 9:2-9.
107. Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993, 78:36-43.
108. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989, 70:928-934.
109. Zech DF, Grond SU, Lynch J, et al. Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 1992, 50:293-301.
110. Gourlay GK, Mather LE Pharmacokinetics and pharmacodynamics. Transdermal fentanyl 1991, 119-140. Springer-Verlag, Berlin. K.A. Lehmann, D. Zech (Eds.).
111. Sandler AN, Baxter AD, Katz S, et al. A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects. Anesthesiology 1994, 81:1169-1180.
112. Streisand SB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991, 75:223-229.
113. Farrar JT, Cleary S, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998, 90:611-616.
114. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998, 16:3238-3245.
115. Fine PG, Marcus M, DeBoer AL, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991, 45:149-153.
116. Inturrisi CE, Unams JG Meperidine biotransformation and central nervous system toxicity in animals and humans. Advances in Pain Research and Therapy, vol 8: Opioid Analgesics in the Management of Clinical Pain 1986, 143. Raven Press, New York. K.M. Foley, C.E. Inturrisi (Eds.).
117. Ereshefsky L, Riesenman C, Lam YW Antidepressant drug interactions and the cytochrome P450 system. The role of cyto-chrome P450 2D6. Clin Pharmacokinet 1995, 29(Suppl 1):10-18.
118. Shipton EA Tramadol: present and future. Anaesth Intens Care 2000, 28:363-374.
119. Wilder-Smith CH, Schimke J, Osterwalder B, et al. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994, 5:141-146.
120. Grond S, Radbruch L, Meuser T, Loick G High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999, 18:174-179.
121. Hoskin PS, Hanks GW Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991, 41:326-344.
122. Caruso FS Morphidex pharmacokinetic studies and single dose analgesic efficacy studies in patients with postoperative pain. J Pain Symptom Manage 2000, 19:S31-S36.
123. Goldblum R Long-term safety of morphi-dex?. J Pain Symptom Manage 2000, 19(18):S50-S56.
124. Radbruch L Buprenorphine TDS: Use in daily practice, benefits for patients. Int J Clin Pract Suppl 2003, 133:19-22.
125. Ossipov MH, Laij, Vanderah TW, et al. Induction of pain facilitation by sustained opioid exposure: Relationship to opioid antinociceptive tolerance. Life Sci 2003, 73:783-800.
126. Trujillo KA, Akil H Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991, 251:85-87.
127. Trujillo KA, Akil H Opiate tolerance and dependence: Recent findings and synthesis. New Biol 1991, 3:915-923.
128. Yaksh TL, Onofrio BM Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians. Pain 1987, 31:211-223.
129. Foley K Changing concepts of tolerance to opioids: What the cancer patient has taught us. Current and Emerging Issues in Cancer Pain: Research and Practice 1993, 331-350. Raven, New York. C.R. Chapman, K. Foley (Eds.).
130. Enting RH, Oldenmenger WH, Van Der Rijt CCD, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 2002, 94:3049-3056.
131. Lawlor PG, Turner KS, Hanson S, et al. Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study. Cancer 1998, 82:1167-1173.
132. Ripamonti C, DeConno F, Groff L, et al. Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998, 9:79-83.
133. Morley JS, Watt SWG, Wells SC, et al. Methadone in pain uncontrolled by morphine [letter]. Lancet 1993, 342:1243.
134. Lawlor P, Turner K, Hanson S, et al. Dose ratio between morphine and hydromor-phone in patients with cancer pain: a retrospective study. Pain 1997, 72:79-85.
135. Hunt G, Bruera E Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995, 10:401-404.
136. Doverty M, Somogyi AA, White JM, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain 2001, 93:155-163.
137. Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002, 96:325-328.
138. Mercadante S Expert Rev. Anticancer Ther. 2001, 1(3):487-494.
139. Zebraski SE, Kochenash SM, Raffa RB Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sciences 2000, 66(23):221-231.
140. Chandler S Nebulized opioids to treat dyspnea. Am J Hosp Palliat Care 1999, 16:418-422.
141. Coyne PJ, Viswanathan R, Smith TJ Nebulized fentanyl citrate improves patient's perception of breathing, respiratory rate, and oxygen saturation in dyspnea. J Pain Symptom Manage 2002, 23(2):157-160.
142. Coyne PJ The use of nebulized fentanyl for the management of dyspnea. Clin J Oncol Nurs 2003, 7(3):334-335.
143. Zeppetella G Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain?. Palliat Med 2000, 14(1):57.
144. Pavis H, Wilcock A, Edgecombe J, et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in cancer patients. J Pain Symptom Manage 2002, 24:598-602.
145. Cole L, Hanning CD Review of the rectal use of opioids. J Pain Symptom Manage 1990, 5:118-126.
146. Ripamonti C, Zecca E, Brunelli C, et al. Rectal custom made suppositories can be made by mixing methadone powder in a hydrogenated oil base and solidified in a refrigerator for 45 minutes. Methadone in cancer patients with pain. Ann Oncol 1995, 6:841-843.
147. Bruera E, Watanabe S, Faisinger RL, et al. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995, 62:141-146.
148. Cherny NI, Portenoy RK Cancer pain management. Current strategy. Cancer 1993, 72:3393-3415.
149. Meuret G, Socham H Patient-controlled analgesia (PCA) in the domiciliary care of tumor patients. Cancer Treat Rev 1996, 22(Suppl A):137-140.
150. Patt RB PCA: Prescribing analgesia for home management of severe pain. Geriatrics 1992, 47:69-72.
151. Swanson G, Smith S, Bulich R, et al. Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: A report of 117 patients. J Clin Oncol 1989, 7:1903-1908.
152. Rapp SE, Egan KS, Ross BK, et al. A multidimensional comparison of morphine and hydromorphone patient-controlled analgesia. Anesth Analg 1996, 82:1043-1048.
153. Woodhouse A, Hobbes AF, Mather LE, et al. A comparison of morphine, pethidine and fentanyl in the postsurgical patient-controlled analgesia environment. Pain 1996, 64:115-121.
154. Coda BA, O'Sullivan B, Donaldson G, et al. Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation. Pain 1997, 72:333-346.
155. Coda B, Tanaka A, Jacobson RC, et al. Hydromorphone analgesia after intravenous bolus administration. Pain 1997, 71:41-48.
156. Dunbar PS, Chapman CR, Buckley FP, et al. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA. Pain 1996, 68:265-270.
157. Inturrisi CE, Colbum WA, Kaiko RF, et al. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987, 41:392-401.
158. Hug CC, Murphy MR, Rigel EP, et al. Pharmacokinetics of morphine injected intravenously into the anesthetized dog. Anesthesiology 1981, 54:38-47.
159. Scholz S, Steinfath M, Schulz M Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin Pharmacokinet 1996, 31:275-292.
160. Bruera E, Lawlor P Cancer pain management. Acta Anaesthesiol Scand 1997, 41:146-153.
161. Sjogren P, Jonsson T, Jensen NH, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993, 55:93-97.
162. Eisele SH, Grigsby EJ, Dea G Clonazepam treatment of myoclonic contractions associated with high-dose opioids: Case report. Pain 1992, 49:231-232.
163. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989, 36:169-176.
164. Bruera E, Brenneis C, Michaud M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988, 62:407-411.
165. Kerr IG, Sone M, Deangelis C, et al. Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients. Ann Intern Med 1988, 108:554-557.
166. Moulin DE, Kreeft JH, Murray Parsons N, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991, 337:465-468.
167. Waldmann CS, Eason JR, Rambohul E, et al. Serum morphine levels. A comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia 1984, 39:768-771.
168. Paix A, Coleman A, Lees S, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995, 63:263-269.
169. DuPen SL, Peterson DG, Williams A, et al. Infection during chronic epidural catheterization: Diagnosis and treatment. Anesthesiology 1990, 73:905-909.
170. Inagaki Y, Mashimo T, Yoshiya I Time-related differential effects of epidural morphine on the neuraxis. Anesth Analg 1993, 76:308-315.
171. Loper KA, Ready LB, Downey M, et al. Epidural and intravenous fentanyl infusions are clinically equivalent after knee surgery. Anesth Analg 1990, 70:72-75.
172. Glass PS, Estok P, Ginsberg B, et al. Use of patient-controlled analgesia to compare the efficacy of epidural to intravenous fentanyl administration. Anesth Analg 1992, 74:345-351.
173. Ellis DJ, Millar WL, Reisner LS A randomized double-blind comparison of epidural versus intravenous fentanyl infusion for analgesia after cesarean section. Anesthesiology 1990, 72:981-986.
174. Miguel R, Barlow I, Morrell M, et al. A prospective, randomized, double-blind comparison of epidural and intravenous sufentanil infusions. Anesthesiology 1994, 81:346-352.
175. Coda BA, Brown MC, Schaffer RL, et al. A pharmacokinetic approach to resolving spinal and systemic contributions to epi-dural alfentanil analgesia and side-effects. Pain 1995, 62:329-337.
176. Paech MJ, Moore JS, Evans SF Meperidine for patient-controlled analgesia after cesarean section. Intravenous versus epidural administration. Anesthesiology 1994, 80:1268-1276.
177. Chrubasik J, Chrubasik S, Martin E The ideal epidural opioid-fact or fantasy?. Eur J Anaesthesiol 1993, 10:79-100.
178. DuPen SL, Kharasch ED, Williams A, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992, 49:293-300.
179. Appelgren L, Nordborg C, Sjoberg M, et al. Spinal epidural metastasis: Implications for spinal analgesia to treat 'refractory' cancer pain. J Pain Symptom Manage 1997, 13:25-42.
180. Nitescu P, Appelgren L, Linder LE, et al. Epidural versus intrathecal morphine-bupivacaine: assessment of consecutive treatments in advanced cancer pain. J Pain Symptom Manage 1990, 5:18-26.
181. Sjoberg M, Appelgren L, Einarsson S, et al. Long-term intrathecal morphine and bupivacaine in 'refractory' cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 1991, 35:30-43.
182. Amer S, Rawal N, Gustafsson LL Clinical experience of long-term treatment with epidural and intrathecal opioids-a nationwide survey. Acta Anaesthesiol Scand 1988, 32:253-259.
183. Nitescu P, Sjoberg M, Appelgren L, et al. Complications of intrathecal opioids and bupivacaine in the treatment of 'refractory' cancer pain. Clin J Pain 1995, 11:45-62.
184. Ventafridda V, Spoldi E, Caraceni A, et al. Intraspinal morphine for cancer pain. Acta Anaesthesiol Scand Suppl 1987, 85:47-53.
185. Brazenor GA Long term intrathecal administration of morphine: A comparison of bolus injection via reservoir with continuous infusion by implanted pump. Neurosurgery 1987, 21:484-491.
186. Plummer JL, Cherry DA, Cousins MJ, et al. Long-term spinal administration of morphine in cancer and non-cancer pain: a retrospective study. Pain 1991, 44:215-220.
187. Crul BJ, Delhaas EM Technical complications during long-term subarachnoid or epidural administration of morphine in terminally ill cancer patients: A review of 140 cases. Reg Anesth 1991, 16:209-213.
188. Devulder I, Ghys L, Dhondt W, et al. Spinal analgesia in terminal care: Risk versus benefit. J Pain Symptom Manage 1994, 9:75-81.
189. Paice JA, Winkelmuller W, Burchiel K, et al. Clinical realities and economic considerations: Efficacy of intrathecal pain therapy. J Pain Symptom Manage 1997, 14:S14-S26.
190. Bedder MD, Burchiel K, Larson A Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991, 6:368-373.
191. Greenberg HS, Taren S, Ensminger WD, et al. Benefit from and tolerance to continuous intrathecal infusion of morphine for intractable cancer pain. J Neurosurg 1982, 57:360-364.
192. Penn RD, Paice JA Chronic intrathecal morphine for intractable pain. J Neurosurg 1987, 67:182-186.
193. Hassenbusch SJ, Pillay PK, Magdinec M, et al. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg 1990, 73:405-409.
194. Onofrio BM, Yaksh TL Long-term pain relief produced by intrathecal morphine infusion in 53 patients. J Neurosurg 1990, 72:200-209.
195. Abram SE Continuous spinal anesthesia for cancer and chronic pain. Reg Anesth 1993, 18:406-413.
196. Cousins MJ, Mather LE Intrathecal and epidural administration of opioids. Anesthesiology 1984, 61:276-310.
197. De Conno F, Caracem A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991, 47:337-339.
198. Follett KA, Hitchon PW, Piper S, et al. Response of intractable pain to continuous intrathecal morphine: A retrospective study. Pain 1992, 49:21-25.
199. Paice SA, Penn RD, Shott S Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manage 1996, 11:71-80.
200. Schultheiss R, Schramm S, Neidhardt S Dose changes in long- and medium-term intrathecal morphine therapy of cancer pain. Neurosurgery 1992, 31:664-669.
201. Wagemans MF, Bakker EN, Zuurmond WW, et al. Intrathecal administration of high-dose morphine solutions decreases the pH of cerebrospinal fluid. Pain 1995, 61:55-59.
202. Jacobson L, Chabal C, Brody MC, et al. Intrathecal methadone and morphine for postoperative analgesia: A comparison of the efficacy, duration, and side effects. Anesthesiology 1989, 70:742-746.
203. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: Report of an expert panel. J Pain Symptom Manage 2000, 20:S37-S43.
204. Winkelmuller M, Winkelmuller W Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996, 85:458-467.
205. Amer S, Amer B Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol Scand 1985, 29:32-36.
206. Shetter AG, Hadley MN, Wilkinson E Administration of intraspinal morphine sulfate for the treatment of intractable cancer pain. Neurosurgery 1986, 18:740-747.
207. Penning JP, Yaksh U Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology 1992, 77:1186-2000.
208. Fink BR Mechanisms of differential axial blockade in epidural and subarachnoid anesthesia. Anesthesiology 1989, 70:851-858.
209. Jamison RN, Taft K, O'Hara SP, et al. Psychosocial and pharmacologic predictors of satisfaction with intravenous patient-controlled analgesia. Anesth Analg 1993, 77:121-125.
210. Chapman CR Psychological aspects of postoperative pain control. Acta Anaesthesiol Belg 1992, 43:41-52.
211. Hardy PA, Wells SC Patient-controlled intrathecal morphine for cancer pain. A method used to assess morphine requirements and bolus doses. Clin J Pain 1990, 6:57-59.
212. Lazorthes Y Intracerebroventricular administration of morphine for control of irreducible cancer pain. Ann NY Acad Sci 1988, 531:123-132.
213. Dennis GC, DeWitty RL Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990, 26:404-407. discussion 407-408.